Ken Griffin Aclaris Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 37,500 shares of ACRS stock, worth $38,625. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,500
Previous 17,300
116.76%
Holding current value
$38,625
Previous $18,000
155.56%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding ACRS
# of Institutions
102Shares Held
53.5MCall Options Held
51KPut Options Held
31.6K-
Bml Capital Management, LLC Zionsville, IN9.4MShares$9.68 Million7.8% of portfolio
-
Black Rock Inc. New York, NY5.2MShares$5.36 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.93MShares$5.08 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.28MShares$3.38 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.27MShares$3.37 Million0.0% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $68.7M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...